statistiche ricercatore

Continente	#
NA - Nord America	1.490
EU - Europa	675
AS - Asia	504
SA - Sud America	71
AF - Africa	15
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	1
Totale	2.758

Nazione	#
US - Stati Uniti d'America	1.458
SG - Singapore	210
DE - Germania	171
CN - Cina	162
IT - Italia	88
SE - Svezia	78
UA - Ucraina	73
IE - Irlanda	68
RU - Federazione Russa	64
BR - Brasile	61
HK - Hong Kong	58
GB - Regno Unito	39
CA - Canada	26
VN - Vietnam	24
FR - Francia	18
IN - India	18
BE - Belgio	16
DK - Danimarca	15
FI - Finlandia	15
BD - Bangladesh	7
AR - Argentina	6
MX - Messico	6
NL - Olanda	6
EG - Egitto	5
IQ - Iraq	4
PL - Polonia	4
RO - Romania	4
TR - Turchia	4
ZA - Sudafrica	4
AT - Austria	3
EC - Ecuador	3
IR - Iran	3
KR - Corea	3
PK - Pakistan	3
ES - Italia	2
EU - Europa	2
LT - Lituania	2
MA - Marocco	2
RS - Serbia	2
TN - Tunisia	2
AE - Emirati Arabi Uniti	1
AL - Albania	1
BH - Bahrain	1
CH - Svizzera	1
CZ - Repubblica Ceca	1
GA - Gabon	1
ID - Indonesia	1
KG - Kirghizistan	1
KH - Cambogia	1
LB - Libano	1
LU - Lussemburgo	1
MY - Malesia	1
MZ - Mozambico	1
NO - Norvegia	1
NZ - Nuova Zelanda	1
PH - Filippine	1
PT - Portogallo	1
SK - Slovacchia (Repubblica Slovacca)	1
VE - Venezuela	1
Totale	2.758

Nome	#
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib	380
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years	376
Imatinib long term effects study: three years of follow-up and assessment	333
Characterization of compound 584, an Abl kinase inhibitor with lasting effects	328
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells	302
Inhibition of RET tyrosine kinase by SU5416	279
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma	278
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy	265
NPM/ALK co-localizes with, and phosphorylates PSF and other RNA-binding proteins	187
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic	183
Totale	2.911

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	260	0	0	0	0	0	100	40	49	47	19	2	3
2021/2022	149	5	12	18	8	7	17	7	4	5	18	15	33
2022/2023	325	32	98	37	30	16	39	0	24	14	1	15	19
2023/2024	221	11	10	14	19	28	60	36	9	13	0	2	19
2024/2025	364	19	37	29	30	41	3	30	6	19	45	47	58
2025/2026	463	115	37	91	64	142	14	0	0	0	0	0	0
Totale													2.911

Bicocca Open Archive